-
NPT520-34 for ALS Treatment Proceeds to Phase 1 Trial
Neuropore has launched a Phase 1 trial testing NPT520-34 to assess its safety, tolerability, and pharmacokinetic properties in healthy volunteers. Read more about the trial here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.